December 13, 2016 Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
November 18, 2016 Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants
November 15, 2016 Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants
November 14, 2016 Synthetic Biologics Announces Commencement of Public Offering of Common Stock and Warrants
November 1, 2016 Synthetic Biologics Reports Third Quarter 2016 Operational Highlights and Financial Results
October 25, 2016 Synthetic Biologics to Report Third Quarter 2016 Operational Highlights and Financial Results on November 1, 2016
October 6, 2016 Synthetic Biologics Awarded Research Contract from Centers for Disease Control and Prevention (CDC) for Microbiome Assessment and Intervention to Address Antibiotic Resistance
September 20, 2016 Synthetic Biologics Announces Completion of Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase) for the Prevention of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Organisms
